Edition:
United Kingdom

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

2.10USD
14 Jun 2019
Change (% chg)

$0.01 (+0.48%)
Prev Close
$2.09
Open
$2.10
Day's High
$2.14
Day's Low
$2.06
Volume
23,764
Avg. Vol
496,805
52-wk High
$7.39
52-wk Low
$0.81

Latest Key Developments (Source: Significant Developments)

Atossa Genetics Provides Clinical Update
Thursday, 25 Apr 2019 

April 25 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS PROVIDES CLINICAL UPDATE AT THE 4TH ANNUAL PRECISION: BREAST CANCER WORLD RESEARCH AND DEVELOPMENT SUMMIT.ATOSSA GENETICS INC - DOSING HAS BEEN COMPLETED IN ATOSSA'S PHASE 2 CLINICAL STUDY OF TOPICAL ENDOXIFEN TO REDUCE MAMMOGRAPHIC BREAST DENSITY..ATOSSA GENETICS INC - ANALYSIS OF PHASE 2 RESULTS IS UNDERWAY AND EXPECTED TO BE ANNOUNCED THIS QUARTER..  Full Article

Atossa Genetics Announces Year End 2018 Financial Results
Thursday, 28 Mar 2019 

March 28 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS ANNOUNCES YEAR END 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.ATOSSA GENETICS INC - IN MARCH 2019 RECEIVED $11.3 MILLION IN ADDITIONAL CASH FROM EXERCISE OF PREVIOUSLY OUTSTANDING WARRANTS..ATOSSA GENETICS INC - AS OF DECEMBER 31, 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND RESTRICTED CASH OF $10.5 MILLION.ATOSSA GENETICS INC - EXPECT OUR RESEARCH AND DEVELOPMENT EXPENSES TO INCREASE THROUGHOUT 2019.  Full Article

Atossa Genetics Gets FDA Approval Of Oral Endoxifen For "Expanded Access" As Post-Mastectomy Treatment For A U.S. Breast Cancer Patient
Thursday, 14 Mar 2019 

March 14 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS ANNOUNCES FDA APPROVAL OF ORAL ENDOXIFEN FOR “EXPANDED ACCESS” AS POST-MASTECTOMY TREATMENT FOR A U.S. BREAST CANCER PATIENT.  Full Article

Atossa Genetics Reports Qtrly Loss Per Share $0.64
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.ATOSSA GENETICS - FOR THREE & NINE MONTHS ENDED SEPTEMBER 30, 2018 AND 2017, HAD NO REVENUE & NO ASSOCIATED COST OF REVENUE.ATOSSA GENETICS - AS OF SEPTEMBER 30, 2018, HAD CASH & CASH EQUIVALENTS & RESTRICTED CASH OF $13.0 MILLION.ATOSSA GENETICS INC QTRLY LOSS PER SHARE $0.64.  Full Article

Atossa Genetics Receives Positive Interim Safety Review In Phase 1 Topical Endoxifen Dose Escalation Study
Tuesday, 15 May 2018 

May 15 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS RECEIVES POSITIVE INTERIM SAFETY REVIEW FROM INDEPENDENT SAFETY COMMITTEE IN PHASE 1 TOPICAL ENDOXIFEN DOSE ESCALATION STUDY IN MEN.ATOSSA GENETICS INC - INDEPENDENT SAFETY COMMITTEE REVIEWED BLINDED DATA CONCLUDED STUDY MAY ADVANCE TO FINAL DOSING LEVEL.  Full Article

Atossa Genetics Announces Quarterly Loss Per Share $0.71
Monday, 14 May 2018 

May 14 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.ATOSSA GENETICS INC QUARTERLY LOSS PER SHARE $0.71.  Full Article

Atossa Genetics Announces 2017 Financial Results
Thursday, 8 Mar 2018 

March 8 (Reuters) - Atossa Genetics Inc ::ATOSSA GENETICS ANNOUNCES 2017 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.  Full Article

Atossa Genetics posts Q3 loss per share ‍$0.18​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Atossa Genetics Inc :Atossa Genetics announces third quarter 2017 financial results and provides company update.Atossa Genetics Inc qtrly loss per share ‍$0.18​.  Full Article

L1 Capital Global Opportunities Master Fund reports 9.01 pct passive stake in ‍atossa Genetics, as of Oct. 26
Friday, 3 Nov 2017 

Nov 3 (Reuters) - L1 Capital Global Opportunities Master Fund Ltd: :L1 capital global opportunities master fund ltd reports 9.01% passive stake in ‍atossa genetics inc, as of october 26, 2017 - SEC filing‍​.  Full Article

Empery Asset Management reports 9.01 pct passive stake in Atossa Genetics
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Empery Asset Management LP::Empery Asset Management LP reports 9.01 percent passive stake in Atossa Genetics as of Oct 26 - SEC filing‍​.  Full Article